Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2007 1
2008 1
2011 1
2012 3
2013 5
2014 7
2015 6
2016 12
2017 6
2018 9
2019 12
2020 9
2021 10
2022 7
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K. Roas M, et al. Among authors: hohmann n. Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246. Blood. 2023. PMID: 35981498 Free article.
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC.
Zhou X, An J, Kurilov R, Brors B, Hu K, Peccerella T, Roessler S, Pfütze K, Schulz A, Wolf S, Hohmann N, Theile D, Sauter M, Burhenne J, Ei S, Heger U, Strobel O, Barry ST, Springfeld C, Tjaden C, Bergmann F, Büchler M, Hackert T, Fortunato F, Neoptolemos JP, Bailey P. Zhou X, et al. Among authors: hohmann n. Nat Cancer. 2023 Sep;4(9):1362-1381. doi: 10.1038/s43018-023-00628-6. Epub 2023 Sep 7. Nat Cancer. 2023. PMID: 37679568 Free PMC article.
Women's health is community health.
Hohmann NS. Hohmann NS. J Am Pharm Assoc (2003). 2019 May-Jun;59(3):302-303. doi: 10.1016/j.japh.2019.04.003. J Am Pharm Assoc (2003). 2019. PMID: 31101312 No abstract available.
CYP3A activity: towards dose adaptation to the individual.
Hohmann N, Haefeli WE, Mikus G. Hohmann N, et al. Expert Opin Drug Metab Toxicol. 2016 May;12(5):479-97. doi: 10.1517/17425255.2016.1163337. Epub 2016 Mar 26. Expert Opin Drug Metab Toxicol. 2016. PMID: 26950050 Review.
Perceived appropriateness of medication adherence incentives.
Hastings TJ, Hohmann NS, Jeminiwa R, Hansen RA, Qian J, Garza KB. Hastings TJ, et al. Among authors: hohmann ns. J Manag Care Spec Pharm. 2021 Jun;27(6):772-778. doi: 10.18553/jmcp.2021.27.6.772. J Manag Care Spec Pharm. 2021. PMID: 34057397 Free PMC article.
Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N, Sprick MR, Pohl M, Ahmed A, Burhenne J, Kirchner M, Le Cornet L, Kratzmann M, Hajda J, Stenzinger A, Steindorf K, Delorme S, Schlemmer HP, Riethdorf S, van Schaik R, Pantel K, Siveke J, Seufferlein T, Jäger D, Haefeli WE, Trumpp A, Springfeld C. Hohmann N, et al. Clin Transl Sci. 2023 Dec;16(12):2483-2493. doi: 10.1111/cts.13661. Epub 2023 Nov 3. Clin Transl Sci. 2023. PMID: 37920921 Free PMC article.
Current published evidence on barriers and proposed strategies for genetic testing implementation in health care settings: A scoping review.
Fahim SM, Alexander CSW, Qian J, Ngorsuraches S, Hohmann NS, Lloyd KB, Reagan A, Hart L, McCormick N, Westrick SC. Fahim SM, et al. Among authors: hohmann ns. J Am Pharm Assoc (2003). 2023 Jul-Aug;63(4):998-1016. doi: 10.1016/j.japh.2023.04.022. Epub 2023 Apr 28. J Am Pharm Assoc (2003). 2023. PMID: 37119989 Review.
82 results